340 related articles for article (PubMed ID: 15172423)
1. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy.
Yasunari K; Maeda K; Watanabe T; Nakamura M; Yoshikawa J; Asada A
J Am Coll Cardiol; 2004 Jun; 43(11):2116-23. PubMed ID: 15172423
[TBL] [Abstract][Full Text] [Related]
2. Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy.
Fogari R; Zoppi A; Mugellini A; Maffioli P; Preti P; Derosa G
Expert Opin Pharmacother; 2012 Jun; 13(8):1091-9. PubMed ID: 22515416
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
4. A selective angiotensin receptor antagonist, Valsartan, produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness.
Suzuki H; Nakamoto H; Okada H; Sugahara S; Kanno Y
Adv Perit Dial; 2003; 19():59-66. PubMed ID: 14763035
[TBL] [Abstract][Full Text] [Related]
5. Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension.
Anan F; Takahashi N; Ooie T; Yufu K; Hara M; Nakagawa M; Yonemochi H; Saikawa T; Yoshimatsu H
Eur J Clin Pharmacol; 2005 Jul; 61(5-6):353-9. PubMed ID: 15918057
[TBL] [Abstract][Full Text] [Related]
6. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.
Thürmann PA; Kenedi P; Schmidt A; Harder S; Rietbrock N
Circulation; 1998 Nov; 98(19):2037-42. PubMed ID: 9808602
[TBL] [Abstract][Full Text] [Related]
7. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design.
Mann J; Julius S
Blood Press; 1998 May; 7(3):176-83. PubMed ID: 9758088
[TBL] [Abstract][Full Text] [Related]
8. The effect of valsartan on left ventricular myocardial functions in hypertensive patients with left ventricular hypertrophy.
Kucukler N; Kurt IH; Topaloglu C; Gurbuz S; Yalcin F
J Cardiovasc Med (Hagerstown); 2012 Mar; 13(3):181-6. PubMed ID: 22306782
[TBL] [Abstract][Full Text] [Related]
9. Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy.
Baser O; Andrews LM; Wang L; Xie L
J Med Econ; 2011; 14(5):576-83. PubMed ID: 21728914
[TBL] [Abstract][Full Text] [Related]
10. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
Ferri C; Croce G; Desideri G
Adv Ther; 2008 Apr; 25(4):300-20. PubMed ID: 18449492
[TBL] [Abstract][Full Text] [Related]
11. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F
Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
[TBL] [Abstract][Full Text] [Related]
12. Comparison of valsartan and amlodipine on ambulatory and morning blood pressure in hypertensive patients.
Eguchi K; Kario K; Hoshide Y; Hoshide S; Ishikawa J; Morinari M; Ishikawa S; Shimada K
Am J Hypertens; 2004 Feb; 17(2):112-7. PubMed ID: 14751651
[TBL] [Abstract][Full Text] [Related]
13. Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension.
Frampton JE; Scott LJ
Am J Cardiovasc Drugs; 2009; 9(5):309-30. PubMed ID: 19791840
[TBL] [Abstract][Full Text] [Related]
14. Valsartan Amlodipine Randomized Trial (VART): design, methods, and preliminary results.
Nakayama K; Kuwabara Y; Daimon M; Shindo S; Fujita M; Narumi H; Mizuma H; Komuro I
Hypertens Res; 2008 Jan; 31(1):21-8. PubMed ID: 18360014
[TBL] [Abstract][Full Text] [Related]
15. Effects of candesartan versus amlodipine on home-measured blood pressure, QT dispersion and left ventricular hypertrophy in high-risk hypertensive patients.
Matsuno Y; Minatoguchi S; Fujiwara H;
Blood Press Suppl; 2011 Apr; 1():12-9. PubMed ID: 21247247
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin II antagonism and the heart: valsartan in left ventricular hypertrophy.
Thürmann PA
Cardiology; 1999; 91 Suppl 1():3-7. PubMed ID: 10449888
[TBL] [Abstract][Full Text] [Related]
17. Choice of Antihypertensive Combination Therapy Based on Daily Salt Intake.
Toyoda S; Inami S; Kato T; Tsukada K; Nakamoto A; Kikegawa Y; Suzuki A; Anraku Y; Node K; Inoue T
Am J Med Sci; 2015 Sep; 350(3):160-6. PubMed ID: 26196407
[TBL] [Abstract][Full Text] [Related]
18. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
[TBL] [Abstract][Full Text] [Related]
19. Effects of combined therapy of Xuezhikang Capsule and Valsartan on hypertensive left ventricular hypertrophy and heart rate turbulence.
Gong C; Huang SL; Huang JF; Zhang ZF; Luo M; Zhao Y; Jiang XJ
Chin J Integr Med; 2010 Apr; 16(2):114-8. PubMed ID: 20473735
[TBL] [Abstract][Full Text] [Related]
20. The effect of valsartan on regression of left ventricular hypertrophy in type 2 diabetic patients.
Suzuki K; Kato K; Soda S; Kamimura T; Aizawa Y
Diabetes Obes Metab; 2004 May; 6(3):195-9. PubMed ID: 15056127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
